Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sanofi - American Depositary Shares
(NQ:
SNY
)
48.30
-1.01 (-2.05%)
Streaming Delayed Price
Updated: 1:00 PM EDT, Jul 3, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sanofi - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
36
37
Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
June 06, 2025
From
Pomerantz LLP
Via
GlobeNewswire
RFK Jr. Champions 'Medical Freedom' While Curtailing Access, Say Public Health Experts
June 06, 2025
U.S. Health Secretary Robert F. Kennedy Jr. has championed "medical freedom" while simultaneously limiting access to COVID-19 vaccines and restricting food stamp purchases, creating what public health...
Via
Benzinga
SANOFI-ADR (NASDAQ:SNY) - A Reliable Dividend Stock with Strong Fundamentals
June 05, 2025
Via
Chartmill
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Flowserve Corporation (NYSE – FLS), Streamline Health Solutions, Inc. (Nasdaq – STRM), Sitio Royalties Corp. (NYSE – STR), Vigil Neuroscience, Inc. (Nasdaq – VIGL)
June 04, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
Price Over Earnings Overview: Sanofi
May 21, 2025
Via
Benzinga
Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response
June 02, 2025
Kymera's KT-621 achieved rapid, deep STAT6 degradation and showed a strong safety profile in Phase 1, with the next trials planned through early 2026.
Via
Benzinga
Sanofi To Buy Blueprint Medicines For Up To $9.5B: Retail Sees More Acquisition Offers From European Pharma Companies
June 02, 2025
Sanofi will pay $129 per share in cash at closing, representing a 27% premium to Blueprint’s closing price on Friday of $101.35.
Via
Stocktwits
Moderna's New COVID Vaccine Secures FDA-Clearance For Seniors, At-Risk Individuals
June 02, 2025
Moderna's mNexspike COVID vaccine approved by FDA for older adults and at-risk groups after Phase 3 trial shows improved efficacy and safety profile.
Via
Benzinga
Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout
June 02, 2025
Sanofi will acquire Blueprint Medicines for up to $9.5 billion, gaining Ayvakit and a promising immunology pipeline, including BLU-808 and elenestinib.
Via
Benzinga
Why Blueprint Medicines Shares Are Trading Higher By 27%; Here Are 20 Stocks Moving Premarket
June 02, 2025
Via
Benzinga
US Stocks Likely To Open Lower After A Solid May: 'TACO' Trade And 'Run It Hot' Optimism 'Are Consensus At This Point,' Says Expert
June 02, 2025
U.S. stock futures fell on Monday after a mixed close on Friday. Futures of major benchmark indices were trading lower in premarket.
Via
Benzinga
Campbell's, SAIC And 3 Stocks To Watch Heading Into Monday
June 02, 2025
Via
Benzinga
Benzinga Bulls And Bears: Nvidia, Palantir, Marvell Technology — And Markets Rallied In May
May 31, 2025
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
Via
Benzinga
Regeneron Pharmaceuticals Crashes 12% On A Surprise Sanofi-Tied Failure
May 30, 2025
Regeneron stock crashed Friday after the company's Sanofi-partnered COPD treatment unexpectedly failed in a Phase 3 study.
Via
Investor's Business Daily
Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data
May 30, 2025
Regeneron and Sanofi's COPD drug itepekimab cut exacerbations by 27% in one Phase 3 trial, while the second trial did not meet its main goal.
Via
Benzinga
Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials
May 30, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Robert F. Kennedy Jr. Says CDC Drops COVID Vaccine For 'Healthy' Pregnant Women, Children
May 27, 2025
RFK Jr. says the COVID-19 vaccine is no longer on the CDC's recommended schedule for healthy kids and pregnant women, though the official site still shows it listed.
Via
Benzinga
Sanofi, VNVC Launch Vaccine Manufacturing Facility In Vietnam, Says Report: Retail’s Positive
May 27, 2025
According to Reuters, operations at the new facility are expected to begin by the end of 2027.
Via
Stocktwits
SANOFI-ADR (NASDAQ:SNY) – A Pharmaceutical Stock With Undervalued Potential
May 26, 2025
SANOFI-ADR (SNY) offers strong profitability, an attractive dividend, and undervalued metrics, making it a compelling choice for value investors in the pharmaceutical sector.
Via
Chartmill
Analysts Think These Stocks Could More Than Double in Value
May 23, 2025
Septerna, Intellia, and Novavax have garnered investor attention for their significant upside potential, but investors should beware the risks as well.
Via
MarketBeat
Topics
World Trade
Navitas (NASDAQ: NVTS) Surges on NVIDIA Deal – SNYR, VIGL, XAGE Lead $2 Stock Watch Now, More Inside
May 22, 2025
Via
AB Newswire
Topics
Artificial Intelligence
Sanofi Inks A $470 Million Alzheimer's Deal, Sending This Dollar Stock Flying
May 22, 2025
The company is working on an Alzheimer's treatment that increases the activity of TREM2, a neuroinflammation target.
Via
Investor's Business Daily
Vigil Neuroscience Stock Triples Pre-market On Acquisition By Sanofi: Retail Goes Super Bullish
May 22, 2025
Under the terms of the deal, Sanofi will acquire all outstanding common shares of Vigil for $8 per share in cash at closing.
Via
Stocktwits
Sanofi Boosts Alzheimer's Pipeline With Vigil Neuroscience Acquisition
May 22, 2025
Sanofi (SNY) to acquire Vigil Neuroscience (VIGL) for $470 million in cash, plus potential $2 per share payout. Acquisition excludes monoclonal antibody program and is expected to be finalized in Q3...
Via
Benzinga
Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi
May 21, 2025
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Novavax Scores Key FDA Win, Shares Jump 19% As Sanofi Unlocks Milestone Payment
May 19, 2025
Novavax's COVID-19 vaccine, Nuvaxovid™, receives limited FDA approval and triggers $175M milestone payment. Commercial distribution planned for fall.
Via
Benzinga
SANOFI-ADR (NASDAQ:SNY) – A Reliable Dividend Stock with Strong Fundamentals
May 15, 2025
SANOFI-ADR (SNY) offers a strong 4.27% dividend yield with sustainable payouts, solid profitability, and manageable debt, making it a top pick for income investors.
Via
Chartmill
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030
May 14, 2025
Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states.
Via
Benzinga
Bristol-Myers Squibb Strikes $350 Million Deal To End Hawaii's Plavix Lawsuit
May 13, 2025
Bristol-Myers Squibb will pay $350 million to settle Hawaii's lawsuit over Plavix marketing practices, ending claims without admitting wrongdoing and avoiding trial.
Via
Benzinga
Topics
Lawsuit
Trump’s ‘Most Favored Nation’ Drug Plan Likely To Face Pushback, JP Morgan Analysts Say
May 12, 2025
JPMorgan analysts said President Trump’s "most favored nation" drug pricing order is unlikely to move forward without Congressional support and will likely face legal and industry resistance, limiting...
Via
Stocktwits
Topics
ETFs
Government
Stocks
< Previous
1
2
3
4
5
6
7
8
9
...
36
37
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.